Background: Leptomeningeal metastasis (LM) in breast cancer is associated with a poor
prognosis. Although no randomised trial has demonstrated that intrathecal chemotherapy …

The development of CNS metastasis in patients with solid malignancies represents a turning
point in the disease process. The prevalence of CNS metastasis from breast cancer may be …

Background Disease presentation, prognostic factors, and treatment patterns for patients
with breast cancer with leptomeningeal metastasis are not well characterized. In this study …

Background Leptomeningeal metastasis (LM) is one of the major problems in the
management of metastatic breast cancer; typically, LM has a devastating prognosis and …

Leptomeningeal metastasis (LM) usually occurs late during the course of breast cancer. The
aim of this study was to characterize the clinical features and outcomes of LM based on …

Leptomeningeal carcinomatosis is a devastating disease. Despite its numerous
complications, intrathecal (IT) chemotherapy remains a longstanding treatment for …

Central nervous system (CNS) metastasis from breast cancer may be characterized as either
parenchymal brain metastasis (BM) or leptomeningeal (LM) metastasis. BM are much more …

Background Breast cancer (BC) is one of the solid tumors most commonly associated with
leptomeningeal disease (LMD). LMD carries a devastating prognosis; however, disease …

Background Leptomeningeal metastasis (LM) is a rare complication of metastatic breast
cancer (MBC), with high morbidity/mortality rates. Our study aimed to describe the largest-to …

2070 Background: Around 5% of patients with breast cancers (BC) will develop
leptomeningeal metastasis (LM). The incidence may increase. Methods: We reported the …